Atrasentan in patients with diabetes and chronic kidney disease

Lancet. 2020 Jan 25;395(10220):269. doi: 10.1016/S0140-6736(19)33020-X.

Authors

Vincenzo Sepe¹, Carmelo Libetta²

Affiliations

¹ Unit of Nephrology and Dialysis, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia 27100, Italy. Electronic address: v.sepe@smatteo.pv.it.
² Unit of Nephrology and Dialysis, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia 27100, Italy; Deptartment of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.

PMID: 31982065
DOI: 10.1016/S0140-6736(19)33020-X

No abstract available

Publication types

Letter
Comment

MeSH terms

Atrasentan
Diabetes Mellitus, Type 2*
Double-Blind Method
Humans
Kidney
Renal Insufficiency, Chronic*

Substances

Atrasentan